Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel versus pegylated liposomal doxorubicin for HIV-related Kaposi sarcoma
PACTR202402669706553Phase 3Not yet recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Kaposi sarcoma (KS) and human immunodeficiency virus infection (HIV) comparing Paclitaxel with Pegylated liposomal doxorubicin (2 arms). Primary endpoint: Progression-free survival. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
paclitaxeldoxorubicin
03
Conditions
Kaposi sarcoma (KS)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202402669706553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402669706553.